280
Participants
Start Date
September 30, 2008
Primary Completion Date
May 31, 2010
Study Completion Date
June 30, 2010
SKP FlutiForm HFA pMDI
Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
Investigational site, Kiev
Investigational site, Mexico City
Investigational site, Vinnytsia
Investigational Site, Elizabeth City
Investigational Site, Valrico
Investigational Site, Guadalajara
Investigational Site, Zapopan
Investigational site, Dnipropetrovsk
Investigational site, Dnipropetrovsk
Investigational Site, Toluca
Investigational Site, West Allis
Investigational site, Kharkiv
Investigational site, Zaporizhzhya
Investigational site, Lviv
Investigational Site, Colorado Springs
Investigational site, Donetsk
Investigational site, Donetsk
Investigational Site, Scottsdale
Investigational Site, Villahermosa
Investigational Site, Orange County
Investigational Site, Portland
Investigational Site, Medford
Investigational site, Craiova
Investigational site, Timișoara
Investigational site, Constanța
Investigational Site, East Providence
Investigational Site, Providence
Investigational site, Lima
Investigational site, Lima
Investigational site, Lima
Investigational site, Lima
Investigational site, Lima
Investigational site, Lima
Investigational site, Bucharest
Investigational site, Bucharest
Investigational site, Bucharest
Investigational site, Kyiv
Investigational site, Kyiv
Investigational site, Kyiv
Collaborators (1)
Abbott
INDUSTRY
SkyePharma AG
INDUSTRY